What is ACHR (Acetylcholine Receptor)?
The acetylcholine receptor (AChR) is a specialized protein complex located at the neuromuscular junction that binds the neurotransmitter acetylcholine and converts this chemical signal into electrical activity by opening an ion channel, thereby enabling muscle contraction. 1
Structural Organization
The AChR is a pentameric transmembrane protein complex composed of five subunits arranged around a central ion channel 1. The muscle fiber sarcolemma contains approximately 10,000 acetylcholine receptors per μm² in the specialized folds and invaginations at the neuromuscular junction 1.
Two Distinct Isoforms
- Fetal isoform: Present during prenatal development and involved in neuromuscular system maturation
- Adult isoform: The predominant form after birth, composed of α₂βδε subunits 2
- Re-expression pattern: The fetal form reappears throughout muscle after denervation 2
Functional Mechanism
When acetylcholine is released from the presynaptic motor nerve terminal (containing approximately 500,000 acetylcholine-filled vesicles), it crosses the 30-nm synaptic gap and binds to AChRs 1. This binding opens cation-selective ion channels, generating the endplate potential (EPP) that triggers voltage-gated sodium channels and produces a muscle action potential 2.
Clinical Significance in Anesthesia and Critical Care
Receptor Regulation States
Up-regulation (increased receptor number/sensitivity):
- Increases sensitivity to acetylcholine
- Decreases sensitivity to neuromuscular blocking agents (NMBAs)
- Occurs in: motor neuron lesions, burns, muscle atrophy from disuse, severe trauma/infection, prolonged NMBA use in ICU
- Critical risk: Can cause life-threatening hyperkalemia after succinylcholine administration 3, 1
Down-regulation (decreased receptor number/sensitivity):
- Increases sensitivity to NMBAs
- Classic example: Myasthenia gravis, where antibodies target AChRs
- Results in resistance to succinylcholine but increased sensitivity to non-depolarizing muscle relaxants 3, 1
Contraindications and Dosing Adjustments
Suxamethonium is contraindicated in primary muscle damage (myopathies) and up-regulation states due to risk of rhabdomyolysis and life-threatening hyperkalemia 3.
For myasthenic patients with down-regulated receptors, a 50-75% dose reduction of non-depolarizing muscle relaxants (atracurium, cisatracurium) is commonly required 3.
Pharmacological Interactions
Acetylcholinesterase inhibitors (neostigmine, pyridostigmine, edrophonium) work by preventing acetylcholine breakdown in the synaptic cleft, increasing acetylcholine concentration to compete with NMBAs at the nicotinic receptor 1.
The AChR represents a critical therapeutic target across multiple neurological and neuromuscular disorders, with dysfunction in cholinergic signaling emerging as a convergent mechanism in conditions ranging from Alzheimer's disease to myasthenia gravis 4.